Hematology Stocks
Biotechnology firms in this vertical focus on the development of novel therapies for malignant and non-malignant blood disorders, ranging from rare genetic anemias to aggressive leukemias and lymphomas. Revenue models center on high-value orphan drug designations and long-term patent protection for complex modalities including gene editing, small molecule inhibitors, and cellular immunotherapies.
As of Oct 23, 2026, Hematology has 34 US-listed companies worth $433B combined. The median member moved +3.5% over the past week; SLN led among the 25 largest at +126.6% and GERN trailed at -4.3%.
Companies in Hematology
- GILD – Gilead Sciences Inc, $193B
- BMY – Bristol-Myers Squibb Company, $129B
- ONC – BeiGene, Ltd., $43B
- INCY – Incyte Corporation, $23.7B
- PTGX – Protagonist Therapeutics Inc, $9B
- COGT – Cogent Biosciences Inc, $5.5B
- CRSP – Crispr Therapeutics AG, $4.8B
- ADPT – Adaptive Biotechnologies Corp, $3.9B
- IRON – Disc Medicine Inc., $3B
- NRIX – Nurix Therapeutics Inc, $2.9B
- BEAM – Beam Therapeutics Inc, $2.5B
- SLS – Sellas Life Sciences Group Inc, $2.3B
- AGIO – Agios Pharm, $2.2B
- COAG – Hemab Therapeutics Holdings, Inc. Common Stock, $1.7B
- AAPG – Ascentage Pharma Group International, $1.4B
- KURA – Kura Oncology Inc, $944M
- RIGL – Rigel Pharmaceuticals Inc, $881M
- GERN – Geron Corporation, $771M
- SLN – Silence Therapeutics PLC, $613M
- AUTL – Autolus Therapeutics Ltd, $482M
- EDIT – Editas Medicine Inc, $445M
- FULC – Fulcrum Therapeutics Inc, $279M
- XFOR – X4 Pharmaceuticals Inc, $243M
- KROS – Keros Therapeutics Inc, $222M
- RLYB – Rallybio Corp, $89.9M
- APLM – Apollomics Inc. Class A Ordinary Shares, $67.8M
- PRPO – Precipio Inc, $38.9M
- ATNM – Actinium Pharmaceuticals Inc, $30.6M
- GTBP – GT Biopharma Inc, $14.5M
- KPTI – Karyopharm Therapeutics Inc, $8.8M
- XCUR – Exicure Inc, $7.3M
- SNTI – Senti Biosciences Inc, $7.1M
- MBRX – Moleculin Biotech Inc, $6.3M
- SYRS – Syros Pharmaceuticals Inc, $10,732